Greg Verdine

Greg Verdine is a distinguished scientist and entrepreneur currently serving as a Venture Partner at Andreessen Horowitz and as Co-Founder, President, CEO, CTO, and Director at LifeMine Therapeutics, which focuses on discovering novel human therapeutics from fungal genomes. Verdine holds the title of Erving Professor of Chemistry at Harvard University and has been associated with the institution since 1989. Other notable ventures include co-founding FogPharma, where innovative medicines targeting "undruggable" disease mechanisms are developed, and founding WAVE Life Sciences, which specializes in enhancing oligonucleotide therapeutic applications. Verdine's extensive venture experience encompasses roles at WuXi Healthcare Ventures, Third Rock Ventures, TPG Biotech, and Apple Tree Partners. Educationally, Verdine earned a PhD in Chemistry from Columbia University and completed a postdoctoral fellowship in Molecular Biology at the Massachusetts Institute of Technology.